Literature DB >> 9815597

DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia.

M R Müller1, C Buschfort, J Thomale, C Lensing, M F Rajewsky, S Seeber.   

Abstract

The time course of the formation and persistence of repair-induced DNA lesions such as single-strand breaks (SSBs) were determined in isolated lymphocytes derived from 32 patients with chronic lymphocytic leukemia (CLL) using the single-cell gel electrophoresis (SCGE, "comet") assay. After pulse-exposure to N-ethyl-N-nitrosourea (EtNU), the initial amount of SSBs (t0 SCGE values) and the time periods required to reduce DNA damage by 50% (t50% SCGE values) were determined in nuclear DNA of individual cells. The t0 SCGE and t50% SCGE values varied interindividually between CLL specimens by factors of 16.6 and 8.2, respectively. Regarding cell-to-cell variation, no major subpopulations with significantly different DNA repair capacities were observed in cell specimens from a given patient. In addition, a monoclonal antibody-based immunocytological assay was used to determine the elimination kinetics for the cytotoxic alkylation product O6-ethylguanine from nuclear DNA. A strong correlation was observed between the relative times for SSB repair and the elimination of O6-ethylguanine from nuclear DNA. Because SCGE and immunocytological assay measure different steps of DNA repair, this observation suggests coordinated regulation of the respective repair pathways. With regard to chemosensitivity profiles, a "fast" repair phenotype corresponded to enhanced in vitro resistance to EtNU, 1,3-bis(2-chloroethyl)-1-nitrosourea, or chlorambucil. Accelerated SSB repair and pronounced in vitro resistance to chlorambucil, 1,3-bis(2-chloroethyl)-1-nitrosourea, and EtNU were found in lymphocytes from CLL patients nonresponsive to chemotherapy with alkylating agents. Distinct DNA repair processes thus mediate resistance to alkylating agents in CLL lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815597

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  DNA repair capacity in lymphocytes of nasopharyngeal cancer patients.

Authors:  Norbert H Kleinsasser; Barbara C Wallner; Christiane Wagner; Ernst R Kastenbauer; Ulrich A Harréus
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-12-24       Impact factor: 2.503

2.  Drug resistance and DNA repair in leukaemia.

Authors:  M R Müller; J Thomale; M F Rajewsky; S Seeber
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on raji cells.

Authors:  Maurizio Brigotti; Valentina Arfilli; Domenica Carnicelli; Laura Rocchi; Cinzia Calcabrini; Francesca Ricci; Pasqualepaolo Pagliaro; Pier Luigi Tazzari; Roberta R Alfieri; Pier Giorgio Petronini; Piero Sestili
Journal:  Toxins (Basel)       Date:  2013-02-21       Impact factor: 4.546

Review 4.  Prediction of individual response to anticancer therapy: historical and future perspectives.

Authors:  Florian T Unger; Irene Witte; Kerstin A David
Journal:  Cell Mol Life Sci       Date:  2014-11-12       Impact factor: 9.261

5.  Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.

Authors:  C Paiva; J C Godbersen; A Berger; J R Brown; A V Danilov
Journal:  Cell Death Dis       Date:  2015-07-09       Impact factor: 8.469

6.  DNA damage in acute myeloid leukemia patients of Northern Mexico.

Authors:  Martha I Dávila-Rodríguez; Elva I Cortés-Gutiérrez; Roberto Hernández-Valdés; Karla Guzmán-Cortés; Rosa E De León-Cantú; Ricardo M Cerda-Flores; Enrique Báez-De la Fuente
Journal:  Eur J Histochem       Date:  2017-12-11       Impact factor: 3.188

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.